My watch list  

Membranous glomerulonephritis

Membranous glomerulonephritis
Classification & external resources
ICD-10 N03.2
ICD-9 583.1
DiseasesDB 7970
eMedicine med/885 
MeSH D015433

Membranous glomerulonephritis (MGN), also known as membranous nephropathy, is a slowly progressive disease of the kidney affecting mostly patients between ages of 30 and 50 years. 85% of MGN cases are classified as primary membranous glomerulonephritis -- that is to say, the cause of the disease is idiopathic (unknown). This can also be referred to as idiopathic membranous nephropathy. The remainder is secondary due to :

  • autoimmune conditions (e.g., systemic lupus erythematosus)
  • infections (e.g., syphilis, malaria, hepatitis B)
  • drugs (e.g., captopril, NSAIDs)
  • inorganic salts
  • malignant tumors (in particular, carcinoma of the lung and colon, and melanoma)

The word membranous refers to the glomerular basement membrane of the kidney; glomerulonephritis means "a kidney disease affecting the capillaries of the glomeruli"; nephropathy is a generic term that just refers to any disease of the kidney.



MGN is caused by circulating immune complex. Current research indicates that the majority of the immune complexes are formed via binding of antibodies to antigens in situ to the glomerular basement membrane. The said antigens may be endogenous to (from) the basement membrane, or "planted" from systemic circulation.

The immune complex serves as an activator that triggers a response from the C5b - C9 complements, which form a membrane attack complex (MAC) on the glomerular epithelial cells. This, in turn, stimulates release of proteases and oxidants by the mesangial and epithelial cells, damaging the capillary walls and causing them to become "leaky". In addition, the epithelial cells also seem to secrete an unknown mediator that reduces nephrin synthesis and distribution.


The defining point of MGN is the presence of subepithelial immunoglobulin-containing deposits along the glomerular basement membrane (GBM). By light microscopy, the basement membrane is observed to be diffusively thickened. Using Jones' stain, the GBM appears to have a "spiked" or "holey" appearance. On electron microscopy, subepithelial deposits that nestle against the glomerular basement membrane seems to be the cause of the thickening. Also, the podocytes lose their foot processes.

As the disease progresses, the deposits will eventually be cleared, leaving cavities in the basement membrane. These cavities will later be filled with basement membrane-like material, and if the disease continues even further, the glomeruli will become sclerosed and finally hyalinized.

Immunoflourescence microscopy will reveal typical granular deposition of immunoglobulins and complement along the basement membrane.

Clinical Presentation

Some patients may present as nephrotic syndrome with proteinuria, edema with or without renal failure. Others may be asymptomatic and may be picked up on screening or urinalysis as having proteinuria. A definitive diagnosis of membranous nephropathy requires a kidney biopsy.


Treatment of secondary membranous nephropathy is guided by the treatment of the original disease. For treatment of idiopathic membranous nephropathy, the treatment options include immunosuppressive drugs and non-specific anti-proteinuric measures.

Immunosuppressive therapy

  1. Corticosteroids: They have been tried with mixed results, with one study showing prevention of progression to renal failure without improvement in proteinuria.
  2. Chlorambucil
  3. Cyclosporine
  4. Tacrolimus
  5. Cyclophosphamide
  6. Mycophenolate mofetil

Perhaps the most difficult aspect of membranous glomerulonpehritis is deciding which patients to treat with immunosuppressive therapy as opposed to simple "background" or anti-proteinuric therapies. A large part of this difficulty is due to a lack of ability to predict which patient will progress to end-stage renal disease, or renal disease severe enough to require dialysis. Because the above medications carry risk, treatment should not be initiated without careful consideration as to risk/benefit profile. Of note, corticosteroids (typically Prednisone) alone are of little benefit. They should be combined with one of the other 5 medications, each of which, along with prednisone, has shown some benefit in slowing down progression of membranous nephropathy. It must be kept in mind, however, that each of the 5 medications also carry their own risks, on top of prednisone.

Natural History

About a third of patients have spontaneous remission, another third progress to require dialysis and the last third continue to have proteinuria, without progression of renal failure.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Membranous_glomerulonephritis". A list of authors is available in Wikipedia.
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE